Skip to main content
Top
Published in: BMC Infectious Diseases 1/2015

Open Access 01-12-2015 | Research article

Severe morbidity after antiretroviral (ART) initiation: active surveillance in HIV care programs, the IeDEA West Africa collaboration

Authors: Yao Abo, Marcel Zannou Djimon, Eugène Messou, Eric Balestre, Martial Kouakou, Jocelyn Akakpo, Carin Ahouada, Nathalie de Rekeneire, François Dabis, Charlotte Lewden, Albert Minga, on behalf of the IeDEA West Africa Collaboration

Published in: BMC Infectious Diseases | Issue 1/2015

Login to get access

Abstract

Background

The causes of severe morbidity in health facilities implementing Antiretroviral Treatment (ART) programmes are poorly documented in sub-Saharan Africa. We aimed to describe severe morbidity among HIV-infected patients after ART initiation, based on data from an active surveillance system established within a network of specialized care facilities in West African cities.

Methods

Within the International epidemiological Database to Evaluate AIDS (IeDEA) - West Africa collaboration, we conducted a prospective, multicenter data collection that involved two facilities in Abidjan, Côte d’Ivoire and one in Cotonou, Benin. Among HIV-infected adults receiving ART, events were recorded using a standardized form. A simple case-definition of severe morbidity (death, hospitalization, fever > 38°5C, Karnofsky index < 70%) was used at any patient contact point. Then a physician confirmed and classified the event as WHO stage 3 or 4 according to the WHO clinical classification or as degree 3 or 4 of the ANRS scale.

Results

From December 2009 to December 2011, 978 adults (71% women, median age 39 years) presented with 1449 severe events. The main diagnoses were: non-AIDS-defining infections (33%), AIDS-defining illnesses (33%), suspected adverse drug reactions (7%), other illnesses (4%) and syndromic diagnoses (16%). The most common specific diagnoses were: malaria (25%), pneumonia (13%) and tuberculosis (8%). The diagnoses were reported as syndromic in one out of five events recorded during this study.

Conclusions

This study highlights the ongoing importance of conventional infectious diseases among severe morbid events occurring in patients on ART in ambulatory HIV care facilities in West Africa. Meanwhile, additional studies are needed due to the undiagnosed aspect of severe morbidity in substantial proportion.
Appendix
Available only for authorised users
Literature
3.
go back to reference Moh R, Danel C, Messou E, Ouassa T, Gabillard D, Anzian A, et al. Incidence and determinants of mortality and morbidity following early antiretroviral therapy initiation in HIV-infected adults in West Africa. AIDS. 2007;21(18):2483–91.CrossRefPubMed Moh R, Danel C, Messou E, Ouassa T, Gabillard D, Anzian A, et al. Incidence and determinants of mortality and morbidity following early antiretroviral therapy initiation in HIV-infected adults in West Africa. AIDS. 2007;21(18):2483–91.CrossRefPubMed
4.
go back to reference Seyler C, Messou E, Gabillard D, Inwoley A, Alioum A, Anglaret X. Morbidity before and after HAART initiation in Sub-Saharan African HIV-infected adults: a recurrent event analysis. AIDS Res Hum Retroviruses. 2007;23(11):1338–47.CrossRefPubMed Seyler C, Messou E, Gabillard D, Inwoley A, Alioum A, Anglaret X. Morbidity before and after HAART initiation in Sub-Saharan African HIV-infected adults: a recurrent event analysis. AIDS Res Hum Retroviruses. 2007;23(11):1338–47.CrossRefPubMed
5.
go back to reference Delphine G, Charlotte L, Ibra N, Raoul M, Olivier S, Besigin T-G, et al. Mortality, AIDS-morbidity, and loss to follow-up by current CD4 cell count among HIV-1–infected adults receiving antiretroviral therapy in Africa and Asia: Data From the ANRS 12222 Collaboration. J Acquir Immune Defic Syndr. 2013;62:555–61.CrossRef Delphine G, Charlotte L, Ibra N, Raoul M, Olivier S, Besigin T-G, et al. Mortality, AIDS-morbidity, and loss to follow-up by current CD4 cell count among HIV-1–infected adults receiving antiretroviral therapy in Africa and Asia: Data From the ANRS 12222 Collaboration. J Acquir Immune Defic Syndr. 2013;62:555–61.CrossRef
6.
go back to reference Lawn SD, Harries AD, Anglaret X, Myer L, Wood R. Early mortality among adults accessing antiretroviral treatment programmes in sub-Saharan Africa. AIDS. 2008;22(15):1897–908.CrossRefPubMed Lawn SD, Harries AD, Anglaret X, Myer L, Wood R. Early mortality among adults accessing antiretroviral treatment programmes in sub-Saharan Africa. AIDS. 2008;22(15):1897–908.CrossRefPubMed
7.
go back to reference Losina E, Yazdanpanah Y, Deuffic-Burban S, Wang B, Wolf LL, Messou E, et al. The independent effect of highly active antiretroviral therapy on severe opportunistic disease incidence and mortality in HIV-infected adults in Cote d’Ivoire. Antivir Ther. 2007;12(4):543–51.PubMedPubMedCentral Losina E, Yazdanpanah Y, Deuffic-Burban S, Wang B, Wolf LL, Messou E, et al. The independent effect of highly active antiretroviral therapy on severe opportunistic disease incidence and mortality in HIV-infected adults in Cote d’Ivoire. Antivir Ther. 2007;12(4):543–51.PubMedPubMedCentral
8.
go back to reference Lewden C, Drabo YJ, Zannou DM, Maiga MY, Minta DK, Sow PS, et al. Disease patterns and causes of death of hospitalized HIV-positive adults in West Africa: a multicountry survey in the antiretroviral treatment era. J Int AIDS Soc. 2014;17:18797.CrossRefPubMedPubMedCentral Lewden C, Drabo YJ, Zannou DM, Maiga MY, Minta DK, Sow PS, et al. Disease patterns and causes of death of hospitalized HIV-positive adults in West Africa: a multicountry survey in the antiretroviral treatment era. J Int AIDS Soc. 2014;17:18797.CrossRefPubMedPubMedCentral
9.
go back to reference Namutebi AM, Kamya MR, Byakika-Kibwika P. Causes and outcome of hospitalization among HIV-infected adults receiving antiretroviral therapy in Mulago hospital, Uganda. Afr Health Sci. 2013;13(4):977–85.CrossRefPubMedPubMedCentral Namutebi AM, Kamya MR, Byakika-Kibwika P. Causes and outcome of hospitalization among HIV-infected adults receiving antiretroviral therapy in Mulago hospital, Uganda. Afr Health Sci. 2013;13(4):977–85.CrossRefPubMedPubMedCentral
10.
go back to reference Ogoina D, Obiako RO, Muktar HM, Adeiza M, Babadoko A, Hassan A, et al. Morbidity and mortality patterns of hospitalised adult HIV/AIDS patients in the Era of highly active antiretroviral therapy: a 4-year retrospective review from Zaria, Northern Nigeria. AIDS Res Treat. 2012;2012:940580.PubMedPubMedCentral Ogoina D, Obiako RO, Muktar HM, Adeiza M, Babadoko A, Hassan A, et al. Morbidity and mortality patterns of hospitalised adult HIV/AIDS patients in the Era of highly active antiretroviral therapy: a 4-year retrospective review from Zaria, Northern Nigeria. AIDS Res Treat. 2012;2012:940580.PubMedPubMedCentral
11.
go back to reference Abo Y, Minga A, Menan H, Danel C, Ouassa T, Dohoun L, et al. Incidence of serious morbidity in HIV-infected adults on antiretroviral therapy in a West African care centre, 2003–2008. BMC Infect Dis. 2013;13:607.CrossRefPubMedPubMedCentral Abo Y, Minga A, Menan H, Danel C, Ouassa T, Dohoun L, et al. Incidence of serious morbidity in HIV-infected adults on antiretroviral therapy in a West African care centre, 2003–2008. BMC Infect Dis. 2013;13:607.CrossRefPubMedPubMedCentral
12.
go back to reference Moon TD, Silva WP, Buene M, Morais L, Valverde E, Vermund SH, et al. Bacteremia as a cause of fever in ambulatory, HIV-infected Mozambican adults: results and policy implications from a prospective observational study. PLoS One. 2013;8(12):e83591.CrossRefPubMedPubMedCentral Moon TD, Silva WP, Buene M, Morais L, Valverde E, Vermund SH, et al. Bacteremia as a cause of fever in ambulatory, HIV-infected Mozambican adults: results and policy implications from a prospective observational study. PLoS One. 2013;8(12):e83591.CrossRefPubMedPubMedCentral
13.
go back to reference Coffie PA, Tonwe-Gold B, Tanon AK, Amani-Bosse C, Bedikou G, Abrams EJ, et al. Incidence and risk factors of severe adverse events with nevirapine-based antiretroviral therapy in HIV-infected women. MTCT-Plus program, Abidjan, Cote d’Ivoire. BMC Infect Dis. 2010;10:188.CrossRefPubMedPubMedCentral Coffie PA, Tonwe-Gold B, Tanon AK, Amani-Bosse C, Bedikou G, Abrams EJ, et al. Incidence and risk factors of severe adverse events with nevirapine-based antiretroviral therapy in HIV-infected women. MTCT-Plus program, Abidjan, Cote d’Ivoire. BMC Infect Dis. 2010;10:188.CrossRefPubMedPubMedCentral
14.
go back to reference Minga A, Lewden C, Dohoun L, Abo Y, Emieme A, Coulibaly A, et al. Short communication: Severe symptomatic hyperlactatemia among HIV type 1-infected adults on antiretroviral therapy in Cote d’Ivoire. AIDS Res Hum Retroviruses. 2010;26(9):991–5.CrossRefPubMedPubMedCentral Minga A, Lewden C, Dohoun L, Abo Y, Emieme A, Coulibaly A, et al. Short communication: Severe symptomatic hyperlactatemia among HIV type 1-infected adults on antiretroviral therapy in Cote d’Ivoire. AIDS Res Hum Retroviruses. 2010;26(9):991–5.CrossRefPubMedPubMedCentral
15.
go back to reference Moh R, Danel C, Sorho S, Sauvageot D, Anzian A, Minga A, et al. Haematological changes in adults receiving a zidovudine-containing HAART regimen in combination with cotrimoxazole in Cote d’Ivoire. Antivir Ther. 2005;10(5):615–24.PubMed Moh R, Danel C, Sorho S, Sauvageot D, Anzian A, Minga A, et al. Haematological changes in adults receiving a zidovudine-containing HAART regimen in combination with cotrimoxazole in Cote d’Ivoire. Antivir Ther. 2005;10(5):615–24.PubMed
16.
go back to reference Ali MK, Magee MJ, Dave JA, Ofotokun I, Tungsiripat M, Jones TK, et al. HIV and metabolic, body, and bone disorders: what we know from low- and middle-income countries. J Acquir Immune Defic Syndr. 2014;67 Suppl 1:S27–39. Ali MK, Magee MJ, Dave JA, Ofotokun I, Tungsiripat M, Jones TK, et al. HIV and metabolic, body, and bone disorders: what we know from low- and middle-income countries. J Acquir Immune Defic Syndr. 2014;67 Suppl 1:S27–39.
17.
go back to reference Ekouevi DK, Karcher S, Coffie PA. Strengthening health systems through HIV monitoring and evaluation in Sub-Saharan Africa. Curr Opin HIV AIDS. 2011;6(4):245–50.CrossRefPubMed Ekouevi DK, Karcher S, Coffie PA. Strengthening health systems through HIV monitoring and evaluation in Sub-Saharan Africa. Curr Opin HIV AIDS. 2011;6(4):245–50.CrossRefPubMed
18.
go back to reference Balestre E, Eholie SP, Lokossue A, Sow PS, Charurat M, Minga A, et al. Effect of age on immunological response in the first year of antiretroviral therapy in HIV-1-infected adults in West Africa. AIDS. 2012;26(8):951–7.CrossRefPubMedPubMedCentral Balestre E, Eholie SP, Lokossue A, Sow PS, Charurat M, Minga A, et al. Effect of age on immunological response in the first year of antiretroviral therapy in HIV-1-infected adults in West Africa. AIDS. 2012;26(8):951–7.CrossRefPubMedPubMedCentral
19.
go back to reference Ekouevi DK, Balestre E, Ba-Gomis FO, Eholie SP, Maiga M, Amani-Bosse C, et al. Low retention of HIV-infected patients on antiretroviral therapy in 11 clinical centres in West Africa. Trop Med Int Health. 2010;15 Suppl 1:34–42.CrossRefPubMedPubMedCentral Ekouevi DK, Balestre E, Ba-Gomis FO, Eholie SP, Maiga M, Amani-Bosse C, et al. Low retention of HIV-infected patients on antiretroviral therapy in 11 clinical centres in West Africa. Trop Med Int Health. 2010;15 Suppl 1:34–42.CrossRefPubMedPubMedCentral
27.
go back to reference The IeDEA and ART cohort collaborations. Immunodeficiency at the start of combination antiretroviral therapy in low-, middle- and high-income countries. J Acquir Immune Defic Syndr. 2014;65(1):e8–16.PubMedCentral The IeDEA and ART cohort collaborations. Immunodeficiency at the start of combination antiretroviral therapy in low-, middle- and high-income countries. J Acquir Immune Defic Syndr. 2014;65(1):e8–16.PubMedCentral
29.
go back to reference Campbell JD, Moore D, Degerman R, Kaharuza F, Were W, Muramuzi E, et al. HIV-infected ugandan adults taking antiretroviral therapy with CD4 counts >200 cells/muL who discontinue cotrimoxazole prophylaxis have increased risk of malaria and diarrhea. Clin Infect Dis. 2012;54(8):1204–11.CrossRefPubMed Campbell JD, Moore D, Degerman R, Kaharuza F, Were W, Muramuzi E, et al. HIV-infected ugandan adults taking antiretroviral therapy with CD4 counts >200 cells/muL who discontinue cotrimoxazole prophylaxis have increased risk of malaria and diarrhea. Clin Infect Dis. 2012;54(8):1204–11.CrossRefPubMed
30.
go back to reference Brentlinger PE, Silva WP, Buene M, Morais L, Valverde E, Vermund SH, et al. Management of fever in ambulatory HIV-infected adults in resource-limited settings: prospective observational evaluation of a New Mozambican guideline. J Acquir Immune Defic Syndr. 2014;67(3):304–9.CrossRefPubMed Brentlinger PE, Silva WP, Buene M, Morais L, Valverde E, Vermund SH, et al. Management of fever in ambulatory HIV-infected adults in resource-limited settings: prospective observational evaluation of a New Mozambican guideline. J Acquir Immune Defic Syndr. 2014;67(3):304–9.CrossRefPubMed
31.
go back to reference Reyburn H, Mbatia R, Drakeley C, Carneiro I, Mwakasungula E, Mwerinde O, et al. Overdiagnosis of malaria in patients with severe febrile illness in Tanzania: a prospective study. BMJ. 2004;329(7476):1212.CrossRefPubMedPubMedCentral Reyburn H, Mbatia R, Drakeley C, Carneiro I, Mwakasungula E, Mwerinde O, et al. Overdiagnosis of malaria in patients with severe febrile illness in Tanzania: a prospective study. BMJ. 2004;329(7476):1212.CrossRefPubMedPubMedCentral
32.
go back to reference De Beaudrap P, Etard JF, Diouf A, Ndiaye I, Ndeye GF, Sow PS, et al. Incidence and determinants of new AIDS-defining illnesses after HAART initiation in a Senegalese cohort. BMC Infect Dis. 2010;10:179.CrossRefPubMedPubMedCentral De Beaudrap P, Etard JF, Diouf A, Ndiaye I, Ndeye GF, Sow PS, et al. Incidence and determinants of new AIDS-defining illnesses after HAART initiation in a Senegalese cohort. BMC Infect Dis. 2010;10:179.CrossRefPubMedPubMedCentral
33.
go back to reference de Cherif TK, Schoeman JH, Cleary S, Meintjes GA, Rebe K, Maartens G. Early severe morbidity and resource utilization in South African adults on antiretroviral therapy. BMC Infect Dis. 2009;9:205.CrossRefPubMedPubMedCentral de Cherif TK, Schoeman JH, Cleary S, Meintjes GA, Rebe K, Maartens G. Early severe morbidity and resource utilization in South African adults on antiretroviral therapy. BMC Infect Dis. 2009;9:205.CrossRefPubMedPubMedCentral
34.
go back to reference Anglaret X, Minga A, Gabillard D, Ouassa T, Messou E, Morris B, et al. AIDS and non-AIDS morbidity and mortality across the spectrum of CD4 cell counts in HIV-infected adults before starting antiretroviral therapy in Cote d’Ivoire. Clin Infect Dis. 2012;54(5):714–23.CrossRefPubMed Anglaret X, Minga A, Gabillard D, Ouassa T, Messou E, Morris B, et al. AIDS and non-AIDS morbidity and mortality across the spectrum of CD4 cell counts in HIV-infected adults before starting antiretroviral therapy in Cote d’Ivoire. Clin Infect Dis. 2012;54(5):714–23.CrossRefPubMed
35.
go back to reference Curtis AJ, Marshall CS, Spelman T, Greig J, Elliot JH, Shanks L, et al. Incidence of WHO stage 3 and 4 conditions following initiation of anti-retroviral therapy in resource limited settings. PLoS One. 2012;7(12):e52019.CrossRefPubMedPubMedCentral Curtis AJ, Marshall CS, Spelman T, Greig J, Elliot JH, Shanks L, et al. Incidence of WHO stage 3 and 4 conditions following initiation of anti-retroviral therapy in resource limited settings. PLoS One. 2012;7(12):e52019.CrossRefPubMedPubMedCentral
37.
go back to reference Beauliere A, Toure S, Alexandre PK, Kone K, Pouhe A, Kouadio B, et al. The financial burden of morbidity in HIV-infected adults on antiretroviral therapy in Cote d’Ivoire. PLoS One. 2010;5(6):e11213.CrossRefPubMedPubMedCentral Beauliere A, Toure S, Alexandre PK, Kone K, Pouhe A, Kouadio B, et al. The financial burden of morbidity in HIV-infected adults on antiretroviral therapy in Cote d’Ivoire. PLoS One. 2010;5(6):e11213.CrossRefPubMedPubMedCentral
38.
go back to reference Boyer S, Marcellin F, Ongolo-Zogo P, Abega SC, Nantchouang R, Spire B, et al. Financial barriers to HIV treatment in Yaounde, Cameroon: first results of a national cross-sectional survey. Bull World Health Organ. 2009;87(4):279–87.CrossRefPubMedPubMedCentral Boyer S, Marcellin F, Ongolo-Zogo P, Abega SC, Nantchouang R, Spire B, et al. Financial barriers to HIV treatment in Yaounde, Cameroon: first results of a national cross-sectional survey. Bull World Health Organ. 2009;87(4):279–87.CrossRefPubMedPubMedCentral
39.
go back to reference Dussault G, Fournier P, Letourmy A, editors. L’assurance maladie en Afrique francophone: améliorer l’accès aux soins et lutter contre la pauvreté. Washington, DC: The World Bank; 2006. Dussault G, Fournier P, Letourmy A, editors. L’assurance maladie en Afrique francophone: améliorer l’accès aux soins et lutter contre la pauvreté. Washington, DC: The World Bank; 2006.
40.
go back to reference Munderi P, Grosskurth H, Droti B, Ross DA. What are the essential components of HIV treatment and care services in low and middle-income countries: an overview by settings and levels of the health system? AIDS. 2012;26 Suppl 2:S97–103.CrossRefPubMed Munderi P, Grosskurth H, Droti B, Ross DA. What are the essential components of HIV treatment and care services in low and middle-income countries: an overview by settings and levels of the health system? AIDS. 2012;26 Suppl 2:S97–103.CrossRefPubMed
41.
go back to reference Ross DA, South A, Weller I, Hakim J. HIV treatment and care systems: the way forward. AIDS. 2012;26 Suppl 2:S147–52.CrossRefPubMed Ross DA, South A, Weller I, Hakim J. HIV treatment and care systems: the way forward. AIDS. 2012;26 Suppl 2:S147–52.CrossRefPubMed
Metadata
Title
Severe morbidity after antiretroviral (ART) initiation: active surveillance in HIV care programs, the IeDEA West Africa collaboration
Authors
Yao Abo
Marcel Zannou Djimon
Eugène Messou
Eric Balestre
Martial Kouakou
Jocelyn Akakpo
Carin Ahouada
Nathalie de Rekeneire
François Dabis
Charlotte Lewden
Albert Minga
on behalf of the IeDEA West Africa Collaboration
Publication date
01-12-2015
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2015
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/s12879-015-0910-3

Other articles of this Issue 1/2015

BMC Infectious Diseases 1/2015 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.